Induction vs Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial
Posted inClinical Updates Oncology Radiology Specialties Wellness & Lifestyle

Induction vs Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting distinct safety profiles.
Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial
Posted inOncology Radiology Specialties

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.